Budget impact analysis of breast cancer medications: a systematic review

Figures & data

Fig. 1 PRISMA flow diagram

Table 1 Study characteristics

Table 2 Methodology and BIA results

Table 3 Quality assessment results

Ivanov DA, Dyakov IN, Zyryanov SК. Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price. Farmakoekonomika [Internet]. 2021;14(2):103–114.

 Google Scholar

Elsamany S, Elsisi GH, Hassanin F, Jafal M. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):511–518.

 PubMed Web of Science ®Google Scholar

Pouwels XGLV, Ramaekers BLT, Geurts SME, Erdkamp F, Vriens BEPJ, Aaldering KNA, et al. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. Acta Oncol. 2020;59(9):1123–1130.

 PubMed Web of Science ®Google Scholar

Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res. 2019;19(1):874.

 PubMed Web of Science ®Google Scholar

Avxentyev NA, Lubennikova EV, Frolov MY. Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. Farmakoekonomika [Internet]. 2019;12(4):279–290.

 Google Scholar

Lee S-M, Jung J-H, Suh D, Jung Y-S, Yoo S-L, Kim D-W, et al. Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European Countries. BioDrugs. 2019;33(4):423–436.

 PubMed Web of Science ®Google Scholar

Mistry R, Suri G, Young K, Hettle R, May JR, Brixner D, et al. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Curr Med Res Opin. 2018;34(12):2143–2150.

 PubMed Web of Science ®Google Scholar

Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS ONE. 2017;12(3): e0172731.

 Web of Science ®Google Scholar

Cesarec A, Likić R. Budget impact analysis of biosimilar trastuzumab for the treatment of breast cancer in Croatia. Appl Health Econ Health Policy. 2017;15(2):277–286.

 PubMed Web of Science ®Google Scholar

Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil ZA. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ. 2015;18(3):189–199.

 PubMed Web of Science ®Google Scholar

Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trécan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. J Med Econ. 2013;16(1):96–107.

 PubMedGoogle Scholar

Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ. 2013;16(2):278–288.

 PubMedGoogle Scholar

Purmonen TT, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective. Int J Technol Assess Health Care. 2010;26(2):163–169.

 PubMed Web of Science ®Google Scholar

Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm. 2009;15(6):467–475.

 PubMed Web of Science ®Google Scholar

Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87(2):146–159.

 PubMed Web of Science ®Google Scholar

Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007;25(5):429–442.

 PubMed Web of Science ®Google Scholar

Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clin Ther. 2004;26(9):1546–1561.

 PubMed Web of Science ®Google Scholar

Availability of data and materials

Not applicable.